Dexpramipexole
An investigational drug for neurodegenerative diseases
Dexpramipexole | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Dexpramipexole is a small molecule drug that has been investigated for its potential use in treating neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). It is a chirally pure form of the drug pramipexole, which is used in the treatment of Parkinson's disease.
Mechanism of Action[edit | edit source]
Dexpramipexole is believed to work by enhancing the function of mitochondria, the energy-producing organelles in cells. This enhancement may help protect neurons from degeneration, which is a hallmark of diseases like ALS. The exact mechanism by which dexpramipexole exerts its effects is not fully understood, but it is thought to involve the modulation of mitochondrial function and reduction of oxidative stress.
Clinical Development[edit | edit source]
Dexpramipexole has undergone several clinical trials to assess its efficacy and safety in patients with ALS. Initial studies showed promise, with some patients experiencing a slower progression of the disease. However, a large Phase III clinical trial did not demonstrate a statistically significant benefit in slowing the progression of ALS compared to placebo.
Potential Applications[edit | edit source]
While the primary focus of dexpramipexole research has been on ALS, there is interest in exploring its potential use in other neurodegenerative conditions, such as Huntington's disease and Alzheimer's disease. The drug's ability to modulate mitochondrial function makes it a candidate for diseases characterized by mitochondrial dysfunction.
Challenges and Future Directions[edit | edit source]
The failure of dexpramipexole to show significant efficacy in late-stage clinical trials for ALS has led to a reevaluation of its potential. Researchers are investigating whether different dosing regimens, combination therapies, or targeting specific patient subgroups might yield better results. Additionally, ongoing research into the drug's mechanism of action may uncover new therapeutic targets or applications.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD